All In Biotech

Drug Trial Radar · NCT05414201

A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis

A Multicenter, Open-label, Single-arm Study to Demonstrate the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Chinese Subjects Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate-, Posterior-, or Pan-uveitis

Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

87

Actual

Start

Jul 7, 2022

Primary completion

Jun 10, 2024

Study completion Jun 10, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-infectious intermediate-, posterior- and pan-uveitis (NIIPPU) are sight threatening diseases with a high patient burden and negative impact on quality of life. Corticosteroids remain the mainstay of first-line treatment for NIIPPU in China despite serious side effects associated with long-term and high-dose corticosteroid use. Adalimumab is used to treat NIIPPU in adults who have had inadequate response to corticosteroids, or who need corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. The purpose of this study is to assess adverse events and effectiveness of adalimumab in Chinese participants requiring high dose corticosteroids with NIIPPU. Adalimumab is a conditionally approved drug in China used to treat participants with NIIPPU. All participants will receive the same treatment. Approximately 87 adult participants will be enrolled at approximately 15 sites in China. Participants will receive one subcutaneous loading dose of adalimumab at baseline followed a week later by a lower dose of adalimumab every other week for up to 30 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Non-infectious Intermediate Posterior- or Pan-uveitis

Interventions

  • AdalimumabDrug

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants that achieve quiescence in both eyesTime frame: Week 30

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, CMU /ID# 243054

    Beijing, China

  • Tianjin Medical University Eye Hospital /ID# 243056

    Tianjin, China

  • Xi'an people's hospital/Xi'an fourth hospital /ID# 243371

    Xi'an, China

  • Peking University First Hospital /ID# 243055

    Beijing, Beijing Municipality, China

  • Shanghai General hospital /ID# 247252

    Shanghai, Shanghai Municipality, China

  • The second affiliated hospital of Zhejiang University school of medicine /ID# 247251

    Hangzhou, Zhejiang, China

  • Eye hospital,WMU Zhejiang Eye Hospital /ID# 247253

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.